X-LINKED RETINITIS PIGMENTOSA
Clinical trials for X-LINKED RETINITIS PIGMENTOSA explained in plain language.
Never miss a new study
Get alerted when new X-LINKED RETINITIS PIGMENTOSA trials appear
Sign up with your email to follow new studies for X-LINKED RETINITIS PIGMENTOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Second-Eye gene therapy offers hope for rare vision loss
Disease control OngoingThis study tests a gene therapy given to the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. The therapy uses a harmless virus to deliver a working gene to the retina. Researchers will check safety and whether it improves visi…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 11:55 UTC
-
Gene therapy for inherited blindness enters long-term safety check
Disease control OngoingThis study follows people who received a gene therapy called AAV5-hRKp.RPGR for X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. Researchers are checking for side effects and measuring how well participants see over time. The goal is to understand the…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New gene therapy could slow vision loss in rare eye disease
Disease control OngoingThis study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. The treatment aims to improve or preserve vision by replacing a faulty gene. Participants receive one of two doses or no treat…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE2, PHASE3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:51 UTC